ArticleDermatology and therapy2026
Economic Burden of Hidradenitis Suppurativa in Spain.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHidradenitis suppurativa (HS) is a highly disabling chronic inflammatory disorder affecting up to 1% of the Spanish population. It is a complex disease that requires significant resources and imposes a considerable economic burden. The aim of this study was to assess the economic burden of diagnosed HS in Spain both at patient and population level.
methodsThe study was conducted from a societal perspective using a bottom-up, prevalence-based approach. We evaluated publicly financed direct healthcare costs (consultations, diagnostic tests, inpatient admissions, surgery, comorbidities, treatment), direct nonhealthcare costs (formal and informal care, out-of-pocket expenses), and indirect costs (absenteeism and productivity loss) incurred by patients diagnosed with HS. A sensitivity analysis was conducted to test the uncertainty of the model.
resultsThe mean annual cost of treating all severities of patients with HS in Spain was €39,535.10. The largest cost components across all categories were informal care (46.05%), treatment (18.24%), out-of-pocket expenses (12.76%), loss of work productivity (10.82%), and surgery (5.62%). Moderate and severe patients cost 64.05% (€34,221.92) and 170.53% (€56,432.77) more than mild patients (€20,860.35), respectively. Assuming a prevalence of 1% and a diagnostic rate of 10%, the total economic burden of diagnosed HS in Spain was estimated at €1587 million.
conclusionsHS has a significant economic impact on patients, their families, the healthcare system, and wider society. This is particularly evident among patients with moderate-to-severe HS. To reduce the economic burden and improve quality of life, efforts should be made to prevent the disease from progressing and to ensure that patients remain in the milder stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.